• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

B7-H1 表达上调与肝癌中的巨噬细胞浸润有关。

Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas.

机构信息

Institute of Immunology, School of Medicine, Shandong University, 44# Wenhua Xi Road, 250012 Jinan, China.

出版信息

Cancer Immunol Immunother. 2012 Jan;61(1):101-8. doi: 10.1007/s00262-011-1094-3. Epub 2011 Aug 19.

DOI:10.1007/s00262-011-1094-3
PMID:21853301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11028743/
Abstract

The overexpression of B7-H1 in hepatocellular carcinoma (HCC) mediates HCC immune escape and obstructs the immunotherapy based on tumor-specific CD8+ T cells. Tumor-associated macrophages (TAM) are a major component of cancer-related inflammation and play a central role in tumor promotion. To classify the mechanism underlying the overexpression of B7-H1 in HCC, we examined B7-H1 expression and TAM infiltration in 63 cases of human HCC samples using immunohistochemistry method and found that B7-H1 overexpression was associated with TAM infiltration in HCC tissues. Furthermore, B7-H1 expression was upregulated at both mRNA level and protein level in HCC cells (BEL-7402 and SMMC-7721) cocultured with macrophages in a transwell system. The upregulation of B7-H1 expression induced by macrophage was inhibited by blocking NF-κB or STAT3 signal pathways. These results suggest that overexpression of B7-H1 in HCC may be induced by inflammatory microenvironment involving macrophages and imply that anti-inflammation therapy might be preventive for immune escape and assistant for immunotherapy of HCC.

摘要

B7-H1 在肝细胞癌 (HCC) 中的过度表达介导 HCC 免疫逃逸,并阻碍基于肿瘤特异性 CD8+ T 细胞的免疫治疗。肿瘤相关巨噬细胞 (TAM) 是癌症相关炎症的主要组成部分,在肿瘤促进中发挥核心作用。为了对 HCC 中 B7-H1 过度表达的机制进行分类,我们使用免疫组织化学方法检查了 63 个人 HCC 样本中的 B7-H1 表达和 TAM 浸润情况,发现 B7-H1 过度表达与 HCC 组织中的 TAM 浸润有关。此外,在巨噬细胞共培养的 Transwell 系统中,B7-H1 在 HCC 细胞(BEL-7402 和 SMMC-7721)中的表达在 mRNA 水平和蛋白水平上均上调。由巨噬细胞诱导的 B7-H1 表达上调被阻断 NF-κB 或 STAT3 信号通路所抑制。这些结果表明,HCC 中 B7-H1 的过度表达可能是由涉及巨噬细胞的炎症微环境诱导的,并暗示抗炎治疗可能有助于预防免疫逃逸和辅助 HCC 的免疫治疗。

相似文献

1
Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas.B7-H1 表达上调与肝癌中的巨噬细胞浸润有关。
Cancer Immunol Immunother. 2012 Jan;61(1):101-8. doi: 10.1007/s00262-011-1094-3. Epub 2011 Aug 19.
2
Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.肿瘤相关巨噬细胞中程序性死亡配体 1 蛋白的优先表达及其在肝癌免疫治疗中的潜在作用。
Int J Mol Sci. 2021 Apr 29;22(9):4710. doi: 10.3390/ijms22094710.
3
IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.白细胞介素-1β诱导溶质载体家族7成员11升高通过上调程序性死亡配体1和集落刺激因子1促进肝细胞癌转移。
Hepatology. 2021 Dec;74(6):3174-3193. doi: 10.1002/hep.32062. Epub 2021 Aug 27.
4
Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.肝纤维化通过 GOLM1 介导的 PD-L1 上调促进肝癌中的免疫逃逸。
Cancer Lett. 2021 Aug 10;513:14-25. doi: 10.1016/j.canlet.2021.05.007. Epub 2021 May 14.
5
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.骨桥蛋白诱导集落刺激因子 1 信号破坏肿瘤相关巨噬细胞的迁移,使肝细胞癌对抗 PD-L1 阻断敏感。
Gut. 2019 Sep;68(9):1653-1666. doi: 10.1136/gutjnl-2019-318419. Epub 2019 Mar 22.
6
Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells.TNF-α 和 IFN-γ 信号通路在诱导肝癌细胞 B7-H1 表达中的交互作用。
Cancer Immunol Immunother. 2018 Feb;67(2):271-283. doi: 10.1007/s00262-017-2086-8. Epub 2017 Oct 31.
7
TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.TGF-β1 诱导的 SOX18 升高通过转录上调 PD-L1 和 CXCL12 促进肝细胞癌的进展和转移。
Gastroenterology. 2024 Jul;167(2):264-280. doi: 10.1053/j.gastro.2024.02.025. Epub 2024 Feb 27.
8
Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.库普弗细胞对人肝细胞癌中CD8 + T细胞的抑制作用是由B7-H1/程序性死亡-1相互作用介导的。
Cancer Res. 2009 Oct 15;69(20):8067-75. doi: 10.1158/0008-5472.CAN-09-0901. Epub 2009 Oct 13.
9
Immune checkpoint molecules are regulated by transforming growth factor (TGF)-1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma.免疫检查点分子受转化生长因子 (TGF)-1 诱导的肝癌上皮间质转化调节。
Int J Med Sci. 2021 Apr 22;18(12):2466-2479. doi: 10.7150/ijms.54239. eCollection 2021.
10
FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.FAT10 通过上调肝癌中 PD-L1 的表达诱导免疫抑制。
Apoptosis. 2024 Oct;29(9-10):1529-1545. doi: 10.1007/s10495-024-01982-1. Epub 2024 Jun 2.

引用本文的文献

1
Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.血清白细胞介素-6浓度是预测阿替利珠单抗联合贝伐单抗治疗肝细胞癌患者疗效的有用生物标志物。
J Gastroenterol. 2025 Mar;60(3):328-339. doi: 10.1007/s00535-024-02185-w. Epub 2024 Dec 9.
2
CD58 defines regulatory macrophages within the tumor microenvironment.CD58 在肿瘤微环境中定义了调节性巨噬细胞。
Commun Biol. 2024 Aug 21;7(1):1025. doi: 10.1038/s42003-024-06712-6.
3
Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress.肿瘤相关巨噬细胞在肝细胞癌抗PD-1/PD-L1免疫治疗中的研究进展
Front Pharmacol. 2024 Jun 18;15:1382256. doi: 10.3389/fphar.2024.1382256. eCollection 2024.
4
Exploring Natural Compounds Targeting PD-L1 and STAT3: Toxicogenomic Analysis, Virtual Screening, Molecular Docking, ADMET Evaluation, and Biological Activity Prediction.探索靶向程序性死亡配体1(PD-L1)和信号转导与转录激活因子3(STAT3)的天然化合物:毒理基因组学分析、虚拟筛选、分子对接、药物代谢动力学/药物毒性(ADMET)评估及生物活性预测
Curr Comput Aided Drug Des. 2025;21(3):348-361. doi: 10.2174/0115734099307259240522093710.
5
Circ_0007422 Knockdown Inhibits Tumor Property and Immune Escape of Colorectal Cancer by Decreasing PDL1 Expression in a miR-1256-Dependent Manner.环状 RNA 0007422 通过降低 miR-1256 依赖性的 PDL1 表达来抑制结直肠癌细胞的肿瘤特性和免疫逃逸。
Mol Biotechnol. 2024 Sep;66(9):2606-2619. doi: 10.1007/s12033-023-01040-2. Epub 2024 Jan 22.
6
Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers.免疫耐受机制对原发性和继发性肝癌免疫治疗疗效的影响。
Transl Gastroenterol Hepatol. 2023 Jun 27;8:29. doi: 10.21037/tgh-23-11. eCollection 2023.
7
Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer.趋化因子在结直肠癌进展、化疗耐药、诊断和预后中的作用。
Front Immunol. 2022 Jul 22;13:724139. doi: 10.3389/fimmu.2022.724139. eCollection 2022.
8
Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.新型乙肝病毒多价疫苗中包含的野生型和G145R逃逸突变体的重组乙肝表面抗原(HBsAg),在体外对健康供体白细胞的影响上存在显著差异。
Vaccines (Basel). 2022 Feb 3;10(2):235. doi: 10.3390/vaccines10020235.
9
Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances.肝细胞癌:分子发病机制与治疗进展
Cancers (Basel). 2022 Jan 26;14(3):621. doi: 10.3390/cancers14030621.
10
The Distribution of M2 Macrophage and Treg in Nasopharyngeal Carcinoma Tumor Tissue and the Correlation with TNM Status and Clinical Stage.鼻咽癌肿瘤组织中 M2 巨噬细胞和 Treg 的分布与 TNM 分期和临床分期的关系。
Asian Pac J Cancer Prev. 2021 Nov 1;22(11):3447-3453. doi: 10.31557/APJCP.2021.22.11.3447.

本文引用的文献

1
IL-27 renders DC immunosuppressive by induction of B7-H1.IL-27 通过诱导 B7-H1 使 DC 具有免疫抑制作用。
J Leukoc Biol. 2011 Jun;89(6):837-45. doi: 10.1189/jlb.1209788. Epub 2011 Feb 23.
2
The PD-1 pathway in tolerance and autoimmunity.PD-1 通路在耐受和自身免疫中的作用。
Immunol Rev. 2010 Jul;236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x.
3
Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells.树突状细胞介导的 CTLs 靶向肝癌干细胞。
Cancer Biol Ther. 2010 Aug 15;10(4):368-75. doi: 10.4161/cbt.10.4.12440. Epub 2010 Aug 22.
4
Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence.早期肝细胞癌的治疗:如何预测和预防复发。
Dig Liver Dis. 2010 Jul;42 Suppl 3:S249-57. doi: 10.1016/S1590-8658(10)60513-0.
5
Serum cytokine levels in patients with hepatocellular carcinoma.肝细胞癌患者的血清细胞因子水平。
Eur Cytokine Netw. 2010 Jun;21(2):99-104. doi: 10.1684/ecn.2010.0192. Epub 2010 May 18.
6
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.PD-1 和 PD-L1 的上调促进了肝癌患者 CD8(+) T 细胞的凋亡和术后复发。
Int J Cancer. 2011 Feb 15;128(4):887-96. doi: 10.1002/ijc.25397.
7
Immunity, inflammation, and cancer.免疫、炎症与癌症。
Cell. 2010 Mar 19;140(6):883-99. doi: 10.1016/j.cell.2010.01.025.
8
Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.调节性 T 细胞耗竭增强了肝癌患者体内由肿瘤抗原 NY-ESO-1b 引发的肿瘤特异性 CD8 T 细胞反应,在体外。
Int J Oncol. 2010 Apr;36(4):841-8. doi: 10.3892/ijo_00000561.
9
Macrophages, innate immunity and cancer: balance, tolerance, and diversity.巨噬细胞、先天免疫与癌症:平衡、耐受与多样性。
Curr Opin Immunol. 2010 Apr;22(2):231-7. doi: 10.1016/j.coi.2010.01.009. Epub 2010 Feb 9.
10
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.强烈的肿瘤相关抗原特异性 CD8(+) T 细胞应答可延长肝癌患者肿瘤治疗后的无复发生存期。
J Gastroenterol. 2010 Apr;45(4):451-8. doi: 10.1007/s00535-009-0155-2. Epub 2009 Nov 20.